187660.KQ ADM Korea Inc.
- Market cap
- KRW 386B
- P/E
- -
- P/B
- 16.83x
- ROE
- -29.4%
- Dividend yield
- -
- Fundamental score
- 0.4/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 187660.KQ undervalued?
Graham numberThe Graham number of ADM Korea Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ADM Korea Inc. fundamental analysis
2 of 21 checks passedROE 0/2
Low return on equity (-29.4%), below 10%.
ROA 0/1
Return on assets (-19.8%) is below the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (46.2%) is above the industry median (4.8%).
Revenue Growth 0/2
Revenue shrank 14.6% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (16.8x) is above the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
ADM Korea Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ADM Korea Inc.
Penetrium Bioscience Inc., a contract research organization, provides clinical-related professional services for customer requirements in South Korea. The company offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs. It also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literat…
Full company profileADM Korea Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ADM Korea Inc. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 2.39B | 10.2B | 13.1B | 14.0B | 14.9B | 13.8B | 9.74B | 9.27B | 7.62B |
| Gross Profit | 1.29B | 3.98B | 7.43B | 7.24B | 4.37B | 3.22B | 101M | 33.6M | 221M |
| Operating Income | 99.8M | 851M | 3.53B | 2.09B | -755M | -1.91B | -16.0B | -7.38B | -7.39B |
| EBITDA | - | - | - | - | 1.67B | 539M | -15.5B | -11.8B | -5.35B |
| Net Income | 484M | 764M | 3.77B | 1.92B | 267M | -2.97B | -20.1B | -14.8B | -6.75B |
| EPS | 22 | 35 | 173 | 88 | 13 | -140 | -475 | -256 | -116 |
| Balance Sheet | |||||||||
| Total Assets | 8.55B | 16.5B | 20.7B | 38.4B | 46.3B | 44.2B | 28.5B | 32.8B | 34.1B |
| Total Liabilities | 4.75B | 5.56B | 6.39B | 4.78B | 16.0B | 17.1B | 21.7B | 11.3B | 11.2B |
| Shareholders' Equity | 3.81B | 10.9B | 14.3B | 33.6B | 30.3B | 27.2B | 6.82B | 21.5B | 22.9B |
| Cash & Short-term Investments | 3.05B | 9.40B | 14.7B | 30.8B | 35.1B | 19.0B | 5.84B | 4.78B | 424M |
| Total Debt | - | - | 19.6M | - | - | - | - | - | - |
| Cash Flow | |||||||||
| Operating Cash Flow | 581M | 1.27B | 5.32B | 738M | 904M | -3.08B | -14.3B | -4.47B | -5.01B |
| Capital Expenditure | 0.00 | 62.1M | 75.9M | 1.10B | 1.57B | 625M | 96.7M | 773M | 0.00 |
| Free Cash Flow | - | - | 5.24B | -364M | -668M | -3.70B | -14.4B | -5.25B | -5.01B |
| Ratios | |||||||||
| ROE | 12.7% | 7.0% | 26.3% | 5.7% | 0.9% | -10.9% | -294.6% | -68.9% | -29.4% |
| ROA | 5.7% | 4.6% | 18.2% | 5.0% | 0.6% | -6.7% | -70.4% | -45.2% | -19.8% |
| Net Profit Margin | 20.3% | 7.5% | 28.8% | 13.8% | 1.8% | -21.5% | -206.2% | -159.9% | -88.7% |
| Debt to Equity | - | - | 0.00x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ADM Korea Inc. dividends
ADM Korea Inc. has not paid dividends in the last 8 fiscal years.
Last stock split: 2:1 on Nov 27, 2024.
Who owns ADM Korea Inc.
- Insiders 32.23%
- Institutions 0.00%
- Public & others 67.77%
- Shares outstanding 63.3M
- Free float 23.7M
ADM Korea Inc. company profile
- Company name
- ADM Korea Inc.
- Ticker
- 187660.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- #603, 166 Magokdong-ro, Seoul, South Korea, 07790
- Phone
- 82 2 730 1457
- Website
- penetriumbio.com
About ADM Korea Inc.
Penetrium Bioscience Inc., a contract research organization, provides clinical-related professional services for customer requirements in South Korea. The company offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs. It also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literature screening, and medical device vigilance; and quality assurance services. The company was formerly known as Hyundai ADM Bio Inc. and changed its name to Penetrium Bioscience Inc. in March 2026. Penetrium Bioscience Inc. was founded in 2003 and is based in Seoul, South Korea.
ADM Korea Inc. management
4- Hyun-woo KimCEO & Director · born 1977
- Mr. Seokmin YoonFounder & President
- Mr. Dohyeong NaChief Financial officer
- Ms. Mihyun ChoManaging Director